Steven Gordon and Briskin Family Innovation Grant Program

The next breakthrough could come from anywhere.

City of Hope is blessed with a broad and diverse community of scientists, researchers and clinicians whose energy, creativity and skills reach across multiple disciplines. This makes us a unique incubator of innovation.

Our people are constantly thinking about better ways to beat cancer, and they share those ideas with each other as well as the broader national and international scientific community.

The Steven Gordon and Briskin Family Innovation Grant Program helps turn those ideas into reality.  Each year, the Scientific Advisory Board of the Briskin Center reviews for potential support projects to receive funding through this important program.

It fills a critical gap in the myeloma research funding chain, enabling these professionals — especially younger clinicians and scientists within the field — to test unconventional, out-of-the-box theories at their earliest stages, even before sufficient data is collected to qualify for government and private grant support.

This is how, for example, a talented postdoctoral fellow studying lung cancer might come up with a novel approach, consult with a junior faculty instructor examining leukemia, adapt the work to multiple myeloma and get the project off the ground.

The Steven Gordon and Briskin Family Innovation Grant Program encourages scientists to be bold, to engage widely and to brainstorm strategies that might otherwise never come to life. They will initiate a new generation of clinical trials and greatly expand basic research into the mechanics of multiple myeloma and drug resistance.

Grant Award List

Basic Text Field
  • Scott R. Goldsmith, M.D., Vikram Adhikarla, Ph.D., and Flavia Pichiorri, Ph.D.
    Targeted radiation therapy to circumvent immune exhaustion and potentiate immunotherapies for multiple myeloma
  • Xiuli Wang, Ph.D., and Ryan Urak, Ph.D.
    Refine CS1-CAR design for the treatment of multiple myeloma from bedside to bench
  • Ryan Woodall, Ph.D., Azra Borogovac, M.D., M.S., Flavia Pichiorri, Ph.D., and Alexander Pozhitkov, Ph.D.
    Elucidating the role of immune stability in daratumumab therapy for multiple myeloma


Basic Text Field
  • Nora Heisterkamp, Ph.D.
    Effect of glycosylation on CD38 immunotherapy in leukemia or lymphoma
  • Jianhua Yu, Ph.D.
    Targeting multiple myeloma with BCMA-CAR T cells expressing an NKG2D-CS1 or NKG2D-GPRC5d bispecific antibody
Basic Text Field
  • Li Du, Ph.D., and Steven Rosen, M.D.
    Enhancing myeloma therapeutics through SUMOylation inhibition
  • Kyuwan Lee, Ph.D., and Nitya Nathwani, M.D.
    Telehealth exercise intervention to improve physical function and frailty in multiple myeloma survivors
  • Jianhua Yu, Ph.D.
    Targeting multiple myeloma with BCMA-CAR T cells expressing a CS1-NKG2D bispecific antibody
Basic Text Field
  • Maung Myo Htut, M.D., and Sophia S. Wang, Ph.D.
    Microbiome and treatment outcomes in autologous stem cell transplant multiple myeloma patients
  • Mingye Feng, Ph.D.
    CD47-blockade and bortezomib combination therapy for multiple myeloma treatment
  • Russell Rockne, Ph.D., Jonathan Keats, Ph.D., Vikram Adhikarla, Ph.D., and Flavia Pichiorri, Ph.D.
    Dissecting mechanisms of daratumumab-acquired immune resistance in multiple myeloma
Basic Text Field
  • Guido Marcucci, M.D., Flavia Pichiorri, Ph.D. and Chun-Wei David Chen, Ph.D.
    Exploring the biological significance and the therapeutic relevance of targeting MDM2 TP53 independent functions in myeloma cells
  • Xiuli Wang, M.D., Ph.D., Maung Myo Htut, M.D., and Flavia Pichiorri, Ph.D.
    Immunological profiling of CS1 CAR T cell therapy of multiple myeloma
Basic Text Field
  • Michael Kahn, Ph.D.
    Modulating Wnt signaling in multiple myeloma
  • Flavia Pichiorri, Ph.D., Xiuli Wang, Ph.D., Russell Rockne, Ph.D., and Erasmus Poku
    Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma
  • Michael Rosenzweig, M.D., and Jonathan Keats, Ph.D.
    A Phase 1/2 study of venetoclax, ixazomib, and dexamethasone for relapsed or refractory amyloid light chain or primary amyloidosis and specific characterization of the plasma cell phenotype
  • Joo Y. Song, M.D., and Dustin Schones, Ph.D.
    Comparing the genomic and epigenomic landscape of the plasmablastic variant of plasma cell myeloma with plasmablastic lymphoma
Basic Text Field
  • Flavia Pichiorri, Ph.D.
    Exploring novel diagnostic implications for the use of drug-conjugated Daratumumab (anti-CD38) in myeloma patients
  • Xiuli Wang, Ph.D.
    CAR T cell therapy for multiple myeloma
Basic Text Field
  • Yuan Chen, M.D.
    Targeting c-Myc and proteasome inhibitor resistance in multiple myeloma
  • Sophia Wang, M.D.
    Disentangling the role of obesity, diabetes, and metformin use on multiple myeloma risk and survival